Sfoglia per Rivista CANCER BIOLOGY
PEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: A tissue-microarray study with clinic-pathological correlations
2012 Aquino, G; Pannone, G; Santoro, A; Liguori, G; Franco, Renato; Serpico, R; Florio, G; DE ROSA, Alfredo; Mattoni, M; Cozza, V; Botti, G; Losito, S; Longo, F; Staibano, S; Cuda, G; Lo Muzio, L; Sbordone, C; Bufo, P; Grimaldi, A; Caraglia, Michele; DI DOMENICO, Marina
Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials
2014 Staropoli, N; Ciliberto, D; Botta, C; Fiorillo, L; Grimaldi, A; Lama, S; Caraglia, Michele; Salvino, A; Tassone, P; Tagliaferri, P.
"Phase II trial of bevacizumab and dose/dense chemoterapy with cisplatin and metronomic daily oral etoposide in advanced non small cell lung cancer patients"
2011 Correale, P; Botta, C; Basile, A; Pagliuchi, M; Licchetta, A; Martellucci, I; Bestoso, E; Apollinari, S; Addeo, R; Misso, Gabriella; Romano, O; Abbruzzese, A; Lamberti, Monica; Luzzi, L; Gotti, G; Rotundo, M; Caraglia, Michele; Tagliaferri, P.
Pyk2 and Cyr61 at the cross-road of cAMP-dependent signalling in invasiveness and neuroendocrine differentiation of prostate cancer
2009 Vitale, G; Gentilini, D; Abbruzzese, A; Caraglia, Michele
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine
2009 Correale, P; Miano, St; Remondo, C; Migali, C; Rotundo, Ms; Macrì, P; Tagliaferri, P; Tassone, P; Caraglia, Michele; Gotti, G; Francini, G.
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
2011 Di Martino, Mt; Arbitrio, M; Leone, E; Guzzi, Ph; Rotundo, Ms; Ciliberto, D; Tomaino, V; Fabiani, F; Talarico, D; Sperlongano, Pasquale; Doldo, P; Cannataro, M; Caraglia, Michele; Tassone, P; Tagliaferri, P.
Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.
2014 Marvaso, G; Barone, A; Amodio, N; Raimondi, L; Agosti, V; Altomare, E; Scotti, V; Lombardi, A; Bianco, R; Bianco, C; Caraglia, Michele; Tassone, P; Tagliaferri, P.
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
2015 Ciliberto, Domenico; Staropoli, Nicoletta; Caglioti, Francesca; Gualtieri, Simona; Fiorillo, Lucia; Chiellino, Silvia; De Angelis, Antonina Maria; Mendicino, Francesco; Botta, Cirino; Caraglia, Michele; Tassone, Pierfrancesco; Tagliaferri, Pierosandro
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
2013 Botta, C; Barbieri, V; Ciliberto, D; Rossi, A; Rocco, D; Addeo, R; Staropoli, N; Pastina, P; Marvaso, G; Martellucci, I; Guglielmo, A; Pirtoli, L; Sperlongano, Pasquale; Gridelli, C; Caraglia, Michele; Tassone, P; Tagliaferri, P; Correale, P.
TARGET-BASED AGENTS IN NEO-ADJUVANT TREATMENT OF LIVER METASTASES FROM COLO-RECTAL CANCER: SECRET WEAPONS IN ANTI-CANCER WAR?
2009 Marra, M; Giudice, A; Arra, C; Vitale, G; Castiglioni, S; Nasti, G; Lombardi, A; Ottaiano, A; Facchini, G; Iaffaioli, Rv; Abbruzzese, A; Caraglia, Michele
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial
2007 DI LORENZO, G; Autorino, Riccardo; DE LAURENTIIS, M; Forestieri, V; Romano, C; Prudente, A; Giugliano, F; Imbimbo, C; Mirone, V; DE PLACIDO, S.
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
2013 Esposito, C; Rachiglio, Am; La Porta, Ml; Sacco, A; Roma, C; Iannaccone, A; Tatangelo, F; Forgione, L; Pasquale, R; Barbaro, A; Botti, G; Ciardiello, Fortunato; Normanno, N.
Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
2016 Nardone, Valerio; Botta, Cirino; Caraglia, Michele; Martino, Elodia Claudia; Ambrosio, Maria Raffaella; Carfagno, Tommaso; Tini, Paolo; Semeraro, Leonardo; Misso, Gabriella; Grimaldi, Anna; Boccellino, Mariarosaria; Facchini, Gaetano; Berretta, Massimiliano; Vischi, Gianluca; Rocca, Bruno Jim; Barone, Aurora; Tassone, Pierfrancesco; Tagliaferri, Pierosandro; del Vecchio, Maria Teresa; Pirtoli, Luigi; Correale, Pierpaolo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| PEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: A tissue-microarray study with clinic-pathological correlations | 1-gen-2012 | Aquino, G; Pannone, G; Santoro, A; Liguori, G; Franco, Renato; Serpico, R; Florio, G; DE ROSA, Alfredo; Mattoni, M; Cozza, V; Botti, G; Losito, S; Longo, F; Staibano, S; Cuda, G; Lo Muzio, L; Sbordone, C; Bufo, P; Grimaldi, A; Caraglia, Michele; DI DOMENICO, Marina | |
| Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials | 1-gen-2014 | Staropoli, N; Ciliberto, D; Botta, C; Fiorillo, L; Grimaldi, A; Lama, S; Caraglia, Michele; Salvino, A; Tassone, P; Tagliaferri, P. | |
| "Phase II trial of bevacizumab and dose/dense chemoterapy with cisplatin and metronomic daily oral etoposide in advanced non small cell lung cancer patients" | 1-gen-2011 | Correale, P; Botta, C; Basile, A; Pagliuchi, M; Licchetta, A; Martellucci, I; Bestoso, E; Apollinari, S; Addeo, R; Misso, Gabriella; Romano, O; Abbruzzese, A; Lamberti, Monica; Luzzi, L; Gotti, G; Rotundo, M; Caraglia, Michele; Tagliaferri, P. | |
| Pyk2 and Cyr61 at the cross-road of cAMP-dependent signalling in invasiveness and neuroendocrine differentiation of prostate cancer | 1-gen-2009 | Vitale, G; Gentilini, D; Abbruzzese, A; Caraglia, Michele | |
| Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine | 1-gen-2009 | Correale, P; Miano, St; Remondo, C; Migali, C; Rotundo, Ms; Macrì, P; Tagliaferri, P; Tassone, P; Caraglia, Michele; Gotti, G; Francini, G. | |
| Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. | 1-gen-2011 | Di Martino, Mt; Arbitrio, M; Leone, E; Guzzi, Ph; Rotundo, Ms; Ciliberto, D; Tomaino, V; Fabiani, F; Talarico, D; Sperlongano, Pasquale; Doldo, P; Cannataro, M; Caraglia, Michele; Tassone, P; Tagliaferri, P. | |
| Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. | 1-gen-2014 | Marvaso, G; Barone, A; Amodio, N; Raimondi, L; Agosti, V; Altomare, E; Scotti, V; Lombardi, A; Bianco, R; Bianco, C; Caraglia, Michele; Tassone, P; Tagliaferri, P. | |
| A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? | 1-gen-2015 | Ciliberto, Domenico; Staropoli, Nicoletta; Caglioti, Francesca; Gualtieri, Simona; Fiorillo, Lucia; Chiellino, Silvia; De Angelis, Antonina Maria; Mendicino, Francesco; Botta, Cirino; Caraglia, Michele; Tassone, Pierfrancesco; Tagliaferri, Pierosandro | |
| Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. | 1-gen-2013 | Botta, C; Barbieri, V; Ciliberto, D; Rossi, A; Rocco, D; Addeo, R; Staropoli, N; Pastina, P; Marvaso, G; Martellucci, I; Guglielmo, A; Pirtoli, L; Sperlongano, Pasquale; Gridelli, C; Caraglia, Michele; Tassone, P; Tagliaferri, P; Correale, P. | |
| TARGET-BASED AGENTS IN NEO-ADJUVANT TREATMENT OF LIVER METASTASES FROM COLO-RECTAL CANCER: SECRET WEAPONS IN ANTI-CANCER WAR? | 1-gen-2009 | Marra, M; Giudice, A; Arra, C; Vitale, G; Castiglioni, S; Nasti, G; Lombardi, A; Ottaiano, A; Facchini, G; Iaffaioli, Rv; Abbruzzese, A; Caraglia, Michele | |
| Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial | 1-gen-2007 | DI LORENZO, G; Autorino, Riccardo; DE LAURENTIIS, M; Forestieri, V; Romano, C; Prudente, A; Giugliano, F; Imbimbo, C; Mirone, V; DE PLACIDO, S. | |
| The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies | 1-gen-2013 | Esposito, C; Rachiglio, Am; La Porta, Ml; Sacco, A; Roma, C; Iannaccone, A; Tatangelo, F; Forgione, L; Pasquale, R; Barbaro, A; Botti, G; Ciardiello, Fortunato; Normanno, N. | |
| Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse | 1-gen-2016 | Nardone, Valerio; Botta, Cirino; Caraglia, Michele; Martino, Elodia Claudia; Ambrosio, Maria Raffaella; Carfagno, Tommaso; Tini, Paolo; Semeraro, Leonardo; Misso, Gabriella; Grimaldi, Anna; Boccellino, Mariarosaria; Facchini, Gaetano; Berretta, Massimiliano; Vischi, Gianluca; Rocca, Bruno Jim; Barone, Aurora; Tassone, Pierfrancesco; Tagliaferri, Pierosandro; del Vecchio, Maria Teresa; Pirtoli, Luigi; Correale, Pierpaolo |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile